ScreenerHero

PDSB PDS Biotechnology Corporation

NAS · US · Healthcare · Biotechnology · pdsbiotech.com
1.065USD+1.91%Mkt Cap: 77.19M $P/E: —

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$58.08BUSDP/E 35.4
ARGX
argenx SE
$48.23BUSDP/E 31.4
RVMD
Revolution Medicines, Inc.
$43.05BUSD
UCB
UCB SA
$41.82BUSDP/E 17.8
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
GMAB
Genmab A/S
$21.10BUSDP/E 29.1
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap77.19M USD
Enterprise Value57.26M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-34.50M USD
Revenue/Share—
Last Price1.065 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-2.88
PEG—
EV/EBITDA-2.06
EV/Revenue—
P/S—
P/B-16.33
EPS (TTM)-0.56
EPS (Forward)-0.36
52W Range
0.195264% of range1.550
52W High1.550 USD
52W Low0.1952 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-372.85%
ROA-113.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-27.75M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-17.83%
Net Debt-1.23M USD
Net Debt/EBITDA0.04
Balance Sheet
Debt/Equity1.83
Current Ratio0.57
Quick Ratio0.45
Book Value/Sh-0.06 USD
Cash/Share0.10 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateMar 18, 2019
Splits
Last Split1:20
Split DateMar 18, 2019
Analyst Consensus
Rating—
Target (Mean)4.750 USD
Upside (mean)+346.0%
Target Range4.500 USD – 5.000 USD
4.500+346.0% to mean5.000
# Analysts2
Ownership
Shares Out.72.47M
Float41.55M
Insiders19.11%
Institutions10.70%
Short Interest
Short Ratio0.1d
Short % Float9.08%
Short % Out.8.84%
Shares Short6.41M
Short (prev mo.)1.89M
Technical
SMA 500.5190 (+105.2%)
SMA 2000.7964 (+33.7%)
Beta1.17
S&P 52W Chg16.45%
Avg Vol (30d)32.94M
Avg Vol (10d)14.18M
Technical Indicators
RSI (14)68.2
MACD0.1458
MACD Signal0.0982
MACD Hist.+0.0476
BB Upper1.253 USD
BB Middle0.6784 USD
BB Lower0.1042 USD
BB Width169.28%
ATR (14)0.1467 USD
Vol Ratio (20d)0.11x